Syra HealthSYRA -3.02%12 Return-on-Tangible-Equity is 43.22% as of Mar. 2026. GuruFocus rates SYRA with a GF Score™ of 12/100 and a GF Value™ of $0.23 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 579 Healthcare Providers & Services companies, Syra Health ranks worse than 80.66% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Syra Health's annualized net income for the quarter that ended in Mar. 2026 was $0.96 Mil. Syra Health's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $2.23 Mil. Therefore, Syra Health's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 43.22%.
The historical rank and industry rank for Syra Health's Return-on-Tangible-Equity or its related term are showing as below:
SYRA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -602.56 Med: -116.75 Max: -7.97
Current: -7.97
During the past 6 years, Syra Health's highest Return-on-Tangible-Equity was -7.97%. The lowest was -602.56%. And the median was -116.75%.
SYRA's Return-on-Tangible-Equity is ranked worse than 80.66% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.13
vs SYRA: -7.97
Syra Health (OTCPK:SYRA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Syra Health Return-on-Tangible-Equity Related Terms
Syra Health Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Syra Health's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SYRA vs NIVF, BICX, HLYK: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Syra Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syra Health Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Syra Health's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Syra Health's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 43.22% mean?
Syra Health (SYRA) has a Return-on-Tangible-Equity of 43.22% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Syra Health and its competitors. According to the industry distribution chart, Syra Health ranks #467 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 80.7%.
Is Syra Health's Return-on-Tangible-Equity too high?
Syra Health's current Return-on-Tangible-Equity is 43.22%. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.13. Syra Health's value of 43.22% is 326.7% above this industry median. Based on the distribution chart, Syra Health ranks #467 out of 579 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Syra Health has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Syra Health's Return-on-Tangible-Equity compare to NIVF and BICX?
According to the Healthcare Providers & Services industry distribution chart, Syra Health ranks #467 out of 579 companies for Return-on-Tangible-Equity. This places Syra Health in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.13. Syra Health's value of 43.22% is 326.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.13, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syra Health's current Return-on-Tangible-Equity of 43.22% is 326.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Syra Health and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syra Health's current Return-on-Tangible-Equity is 43.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syra Health stock overvalued right now?
Based on GuruFocus' analysis, Syra Health (SYRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.23, compared to a current price of $0.71 — trading 207.7% above its estimated fair value. The current Return-on-Tangible-Equity is 43.22% and 326.7% above the Healthcare Providers & Services industry median of 10.13. Syra Health's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Syra Health (SYRA), the current Return-on-Tangible-Equity is 43.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syra Health (SYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Syra Health stock appears to be overvalued.
The current stock price of $0.71 is trading 207.7% above its estimated GF Value™ of $0.23.
GuruFocus considers Syra Health to be Significantly Overvalued.
Key valuation signals for SYRA:
Return-on-Tangible-Equity: 43.22%
GF Value™: $0.23 vs. price of $0.71 (207.7% above fair value)
Industry Position: 326.7% above the Healthcare Providers & Services median (#467 of 579)
No single metric tells the full story. See the SYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syra Health Corp is an integrated healthcare solutions company serving government and commercial healthcare organizations. It delivers end-to-end capabilities across population health, behavioral and mental health, digital health, health education and training, and healthcare workforce development and staffing. The various services offered by the company include Syrenity, a mental health application providing preventative care and interventions for behavioral and mental health conditions; SyraBot, a chatbot offering members access to necessary information via the firm's AI-powered customer support chat system; CarePlus, an electronic medical records solution designed for small to mid-sized healthcare organizations; and patient engagement and education services, among others.
12GF Score
Get the complete analysis for SYRA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYRA has been successfully added to your 
